Harvard College

Vertex Pharmaceuticals, Inc.

Joshua Syken

Jian Jim Wang

Albert Charles Pierce

Francois Maltais

Robert J Davies

Emanuele Perola

Huai Gao

Anne-Laure Grillot

Jingrong Cao

Yusheng Liao

James A Henderson

Wenxin Gu

David Messersmith

Ronald Lee Grey, Jr

Philip N Collier

Michael Paul DeNinno

Sanjay Shivayogi Magavi

James Daniel Frantz

Elizabeth Jin-Sun Ryu

Meghan Elise Cockerill

Elisabeth Doyle

Brian Anthony Goldman

Adrianne Lynn Kolpak

Raul Eduardo Krauss

Raul Eduardo Krauss Irarrazaval

Carla J Shatz

Karl M&uuml;nger

Carla Shatz

The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases:  The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles for the treatment of demyelinating dieases

The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

Triazoles for the treatment of Demyelinating Diseases

Class I major histocompatibility complex, is required in the activity-dependent refinement and plasticity of connections in the developing and adult central nervous system, demonstrating that molecules can perform critical roles in both systems. Similarities in the cellular signaling mechanisms of the immune and nervous systems provide for development of therapeutic and diagnostic agents in abnormal neuronal cellular function.

Immunocellular receptors related to neurological disorders and therapeutic uses thereof

The invention provides isolated nucleic acids and vectors encoding two splice forms of Tid1 (Tid-1L and Tid-1S) and cells and non-human organisms comprising such. The invention further provides methods for modulating apoptosis in a cell by modulating the amount and/or activity of these two splice forms relative to each other. Such methods can be used in vivo and in vitro, e.g., in cell cultures, for either making cells more susceptible to apotosis or more resistant to it.

Methods and reagents to regulate apoptosis

Growing community of inventors

Jamaica Plain, MA, United States of America

Joshua Syken